NASDAQ:SLS SELLAS Life Sciences Group Q3 2025 Earnings Report $9.18 +0.60 (+6.99%) Closing price 04:00 PM EasternExtended Trading$9.18 0.00 (-0.05%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast SELLAS Life Sciences Group EPS ResultsActual EPS-$0.06Consensus EPS -$0.08Beat/MissBeat by +$0.02One Year Ago EPSN/ASELLAS Life Sciences Group Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASELLAS Life Sciences Group Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time4:00PM ETUpcoming EarningsSELLAS Life Sciences Group's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) SELLAS Life Sciences Group Earnings HeadlinesSLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS1 hour ago | finance.yahoo.comSLS stock surges toward fifth weekly rise: CEO touts GPS as lifeline for elderly patients as cancer summit loomsMay 27 at 1:29 PM | msn.comSMX Could Be One of the Most Interesting Small Caps Right NowSMX (Security Matters) Public Limited is developing molecular-level markers embedded into plastics, fuels, metals, textiles, and industrial commodities to give physical materials a digital identity. Its Digital Material Passport technology targets verification of origin, recycled content, and lifecycle data across global supply chains - a market growing more compliance-driven by the day. As governments tighten recycled-content reporting standards, SMX is positioning itself inside one of the decade's most consequential industrial shifts.May 28 at 1:00 AM | Smallcaps Daily (Ad)SLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial ReadoutMay 26 at 7:25 PM | finance.yahoo.comSLS stock heads for their best month this year ahead of key AML trial readoutMay 26 at 7:25 PM | msn.comSellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish SignalMay 22, 2026 | seekingalpha.comSee More SELLAS Life Sciences Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SELLAS Life Sciences Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SELLAS Life Sciences Group and other key companies, straight to your email. Email Address About SELLAS Life Sciences GroupSELLAS Life Sciences Group (NASDAQ:SLS) is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells. The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1. GPS is currently being evaluated in ongoing Phase II/III clinical trials for acute myeloid leukemia (AML), malignant pleural mesothelioma and ovarian cancer. SELLAS is also exploring combination regimens of GPS with immune checkpoint inhibitors to enhance antitumor activity, as well as next-generation cellular approaches intended to broaden its therapeutic platform beyond peptide vaccines. SELLAS conducts its clinical trials across multiple geographies, including North America, Europe and Japan, leveraging collaborations with leading academic research centers and contract research organizations. These partnerships enable the company to advance its programs efficiently through regulatory pathways and to access patient populations in key oncology indications. The management team at SELLAS brings together seasoned executives and scientific leaders with extensive experience in oncology drug development. The company remains committed to translating its WT1-targeted immunotherapy approach into new treatment options for patients with high-unmet-need cancers.View SELLAS Life Sciences Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake and the Snowballing Impact of its AI FlywheelThis Quantum Computing Stock May Be Closer to a Breakout Than You ThinkMicrosoft Is Spending Billions on AI, But Investors Aren’t Buying ItSemtech’s Explosive Rally May Only Be Getting StartedBath & Body Works Stock Surged Despite Falling Sales—Here’s WhyAbercrombie Rallies as Strong Q1 Earnings Extend Winning StreakDick’s Sporting Goods Isn’t Done Winning Yet Upcoming Earnings Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
